Galectin Therapeutics Inc.
GALT
$3.98
-$0.18-4.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.57M | 5.68M | 5.86M | 5.88M | 5.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.02M | 40.68M | 42.43M | 39.57M | 39.67M |
| Operating Income | -34.02M | -40.68M | -42.43M | -39.57M | -39.67M |
| Income Before Tax | -40.34M | -45.19M | -47.05M | -45.08M | -44.29M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -40.34 | -45.19 | -47.05 | -45.08 | -44.29 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -40.34M | -45.19M | -47.05M | -45.08M | -44.29M |
| EBIT | -34.02M | -40.68M | -42.43M | -39.57M | -39.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.64 | -0.72 | -0.76 | -0.73 | -0.78 |
| Normalized Basic EPS | -0.40 | -0.45 | -0.47 | -0.45 | -0.45 |
| EPS Diluted | -0.64 | -0.72 | -0.76 | -0.73 | -0.78 |
| Normalized Diluted EPS | -0.40 | -0.45 | -0.47 | -0.45 | -0.45 |
| Average Basic Shares Outstanding | 251.68M | 250.46M | 249.23M | 248.35M | 245.78M |
| Average Diluted Shares Outstanding | 251.68M | 250.46M | 249.23M | 248.35M | 245.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |